01—Abstract
Summary
Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
On November 5, 2025, Halozyme Therapeutics, Inc. entered into Amendment No. 3 to its Credit Agreement dated May 24, 2022.
The amendment extended the maturity of the existing revolving credit facility and increased total revolving commitments to $750,000,000a. The Amended Revolving Credit Facility matures on the earlier of November 5, 2030 and the Springing Revolver Maturity Date. As of November 5, 2025, after giving effect to the amendment, the company had $0 of outstanding borrowings under the Credit Agreement.
The credit agreement requires a maximum consolidated net leverage ratio of 4.50 to 1.00 and a minimum consolidated interest coverage ratio of 3.00 to 1.00, measured at each fiscal quarter end. The net leverage covenant increases by 0.50 to 1.00, to no more than 5.00 to 1.00, for three fiscal quarters after a material acquisition. The same day, the company announced a proposed offering, subject to market conditions, of $650.0 millionb of convertible senior notes due 2031 and $650.0 million of convertible senior notes due 2032.
The initial purchasers also have a 13-day option to buy up to an additional $100.0 millionc of each series. The notes are senior, unsecured obligations, with the 2031 Notes maturing February 15, 2031 and the 2032 Notes maturing November 15, 2032. The company intends to settle conversions in cash and, where applicable, shares of common stock, at its election.
Net proceeds are expected to fund capped call transactions, privately negotiated repurchases of the company's outstanding 0.25%d convertible senior notes due 2027 and 1.00% convertible senior notes due 2028, and general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions. The filing states that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the convertible notes, and could result in a higher effective conversion price for the new notes. The filing also notes that the notes have not been registered under the Securities Act and are being offered only to qualified institutional buyers under Rule 144A.
02—Key points
Key Highlights
- Revolving credit facility increased to $750,000,000 in total commitments under Amendment No. 3 to the Credit Agreement.
- Amended Revolving Credit Facility matures on the earlier of November 5, 2030 and the Springing Revolver Maturity Date.
- No outstanding borrowings under the Credit Agreement as of November 5, 2025, after giving effect to the amendment.
- Financial covenants: maximum consolidated net leverage ratio of 4.50 to 1.00 and minimum consolidated interest coverage ratio of 3.00 to 1.00.
- Proposed offering of $650.0 million of convertible senior notes due 2031 and $650.0 million due 2032, with a 13-day option for up to an additional $100.0 million of each series.
- Net proceeds expected to fund capped calls, repurchases of 0.25% notes due 2027 and 1.00% notes due 2028, and general corporate purposes.
- Repurchases and hedging activity by note counterparties could affect the company's common stock price and the effective conversion price of the new notes.
03—Questions
Frequently Asked Questions
How much liquidity is available under the revolving credit facility?
The revolving credit facility has aggregate commitments of $750,000,000 after the amendment. As of November 5, 2025, after giving effect to the amendment, the company had $0 of outstanding borrowings under the Credit Agreement.
When does the amended revolving credit facility mature?
It matures on the earlier of November 5, 2030 and the Springing Revolver Maturity Date, unless extended under the Credit Agreement before that date.
What are the company's principal financial covenants under the credit agreement?
The company must maintain a maximum consolidated net leverage ratio of 4.50 to 1.00 and a minimum consolidated interest coverage ratio of 3.00 to 1.00, measured at the end of each fiscal quarter. After a material acquisition, the net leverage covenant increases by 0.50 to 1.00, to no more than 5.00 to 1.00, for three fiscal quarters.
What securities is the company proposing to offer, and on what terms?
The company proposes to offer, subject to market conditions, $650.0 million of convertible senior notes due 2031 and $650.0 million of convertible senior notes due 2032. These are senior, unsecured obligations that accrue semi-annual interest. The 2031 Notes mature February 15, 2031 and the 2032 Notes mature November 15, 2032. Conversion settlement may be in cash and, where applicable, common stock, at the company's election. Initial conversion rates and interest rates will be set at pricing.
How will the company use the proceeds, and what dilution risks does the filing describe?
Proceeds are expected to fund capped call transactions, privately negotiated repurchases of the 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028, and general corporate purposes. The filing states that capped calls are generally expected to reduce potential dilution from conversion, but dilution still occurs above the cap price. It also states that note repurchases and hedging activity could affect the common stock price and could result in a higher effective conversion price.
04—Continue